Table 1.
Clinical and health parameters.
| Variable | Baseline value (range) | Distribution |
|---|---|---|
| Clinical parameters | ||
| Weibull survival model for OS | ||
| Chemotherapy | Scale = 0.031710, Shape = 1.086298 11 | NA |
| EV + P | Scale = 0.013950, Shape = 1.126849 11 | NA |
| Weibull survival model for PFS | ||
| Chemotherapy | Scale = 0.085880, Shape = 1.110700 11 | NA |
| EV + P | Scale = 0.073244, Shape = 0.848184 11 | NA |
| Rate of post-discontinuation therapy | ||
| EV + P | 0.087 (0.070–0.104) 11 | Beta |
| Chemotherapy | 0.136 (0.101–0.163) 11 | Beta |
| Risk for main AEs in chemotherapy | ||
| Thrombocytopenia | 0.194 (0.155–0.233) 11 | Beta |
| Neutropenia | 0.300 (0.240–0.360) 11 | Beta |
| Anemia | 0.314 (0.251–0.377) 11 | Beta |
| Risk for main AEs in EV + P | ||
| Maculopapular rash | 0.077 (0.062–0.092) 11 | Beta |
| Health parameters | ||
| Utility and disutility | ||
| Utility of PFS | 0.842 (0.674–1.010)15,16 | Beta |
| Utility of PD | 0.840 (0.640–0.960)15,16 | Beta |
| Disutility of AEs (⩾3 grades) | 0.273 (0.218–0.328)13,17 | Beta |
AEs, adverse events; EV + P, enfortumab vedotin plus pembrolizumab; NA, not applicable; OS, overall survival; PD, progressive disease; PFS, progression-free survival.